“基于德尔菲法的AQP4-IgG阳性NMOSD管理国际共识”解读  

Interpretation of“International Delphi Consensus on the Management of AQP4-IgG+NMOSD”

作　　者：黄文娟 全超 HUANG Wen-juan;QUAN Chao(Department of Neurology,Huashan Hospital,Fudan University,Shanghai 200040,China)

机构地区：[1]复旦大学附属华山医院神经内科,上海200040

出　　处：《中国临床神经科学》2024年第6期697-704,共8页Chinese Journal of Clinical Neurosciences

基　　金：国家自然科学基金(编号:82171341)。

摘　　要：视神经脊髓炎谱系疾病(NMOSD)是一种主要累及视神经和脊髓的中枢神经系统自身免疫性炎性疾病,复发率和致残率高,其发病机制主要与水通道蛋白4免疫球蛋白G(AQP4-IgG)抗体有关。自2021年4月中国国家药品监督管理局正式批准萨特利珠单抗用于治疗12岁以上AQP4-IgG阳性的NMOSD患者以来,陆续又有新的单克隆抗体在中国获批治疗NMOSD。但目前国内对于这些药物的规范使用尚无明确的指导性意见。2023年7月,来自15个不同国家或地区的24名专家联合发布了首个“基于德尔菲法的AQP4-IgG阳性NMOSD管理国际共识”(简称“共识”),该“共识”采用改良德尔菲法,就萨特利珠单抗、依库珠单抗和伊奈利珠单抗在AQP4-IgG阳性NMOSD患者中的应用达成了25项声明。文中对该“共识”进行解读,旨在为中国临床医生科学管理AQP4-IgG阳性NMOSD提供参考。Neuromyelitis optica spectrum disorder(NMOSD)is an autoimmune inflammatory disease of the central nervous system that mainly affects the optic nerve and spinal cord.It has a high rate of recurrence and disability.Its pathogenesis is mainly related to aquaporin 4 immunoglobulin G(AQP4-IgG)antibodies.Since satralizumab was approved by National Medical Products Administration(NMPA)for the treatment of AQP4-IgG-seropositive NMOSD in adults and adolescents(≥12 years)in April 2021,new monoclonal antibodies have been approved to treat NMOSD in China.However,there is currently no clear guidance on the standardized use of these drugs.In July 2023,24 experts from 15 different countries or regions jointly released the“International Delphi Consensus on the Management of AQP4-IgG+NMOSD”.The consensus adopted a modified Delphi method and reach 25 statements regarding the use of satralizumab,eculizumab and inelizumab in patients with AQP4-IgG-seropositive NMOSD.This article interprets this consensus and provide a reference for the scientific management of AQP4-IgGseropositive NMOSD by Chinese clinicians.

关 键 词：视神经脊髓炎谱系疾病 水通道蛋白4 免疫球蛋白G 国际共识 德尔菲法 解读 

分 类 号：R744.5[医药卫生—神经病学与精神病学]